CYT003 in Patients With Mild to Moderate Allergic Asthma Not Sufficiently Controlled on Inhaled Glucocorticosteroids
Phase 2
Withdrawn
- Conditions
- Asthma
- Interventions
- Biological: CYT003Biological: Placebo
- First Posted Date
- 2014-03-14
- Last Posted Date
- 2014-05-14
- Lead Sponsor
- Cytos Biotechnology AG
- Registration Number
- NCT02087644
- Locations
- 🇺🇸
University of South Florida, Tampa, Florida, United States
CYT003-QbG10, a TLR9-agonist, for Treatment of Uncontrolled Moderate to Severe Allergic Asthma
Phase 2
Terminated
- Conditions
- Moderate to Severe Allergic Asthma
- Interventions
- Biological: CYT003Biological: Placebo
- First Posted Date
- 2012-08-28
- Last Posted Date
- 2014-05-14
- Lead Sponsor
- Cytos Biotechnology AG
- Target Recruit Count
- 365
- Registration Number
- NCT01673672
- Locations
- 🇺🇦
Cytos Investigator Sites, Vinnytsya, Ivano-Frankivsk, Ukraine
Safety, Tolerability and Pharmacodynamics of CYT013-IL1bQb in Patients With Type 2 Diabetes
- First Posted Date
- 2009-06-18
- Last Posted Date
- 2012-02-13
- Lead Sponsor
- Cytos Biotechnology AG
- Target Recruit Count
- 48
- Registration Number
- NCT00924105
- Locations
- 🇨ðŸ‡
Cytos Investigator sites, Zuerich, Switzerland
CYT003-QbG10 for Treatment of Allergic Asthma Bronchial
- First Posted Date
- 2009-04-30
- Last Posted Date
- 2012-02-13
- Lead Sponsor
- Cytos Biotechnology AG
- Target Recruit Count
- 63
- Registration Number
- NCT00890734
- Locations
- 🇩🇪
Cytos Investigator Sites, Luebeck, Berlin, Wiesbaden, Rodgau, Eisenach, Germany
Dose Finding Study With CYT003-QbG10 in Patients With House Dust Mite Allergy
- First Posted Date
- 2008-12-02
- Last Posted Date
- 2010-11-15
- Lead Sponsor
- Cytos Biotechnology AG
- Target Recruit Count
- 300
- Registration Number
- NCT00800332
- Locations
- 🇷🇴
Cytos Investigator Sites, Targu Mures, Bukarest, Craiova, Iasi, Romania
Safety, Tolerability and Efficacy of a Vaccine Against Essential Hypertension
Phase 2
Completed
- Conditions
- Mild Essential HypertensionModerate Essential Hypertension
- Interventions
- Biological: CYT006-AngQb
- First Posted Date
- 2008-07-04
- Last Posted Date
- 2010-11-15
- Lead Sponsor
- Cytos Biotechnology AG
- Target Recruit Count
- 83
- Registration Number
- NCT00710372
- Locations
- 🇨ðŸ‡
Cytos Biotechnology (Sponsor's Headquarter), Schlieren, Switzerland
Study to Evaluate Safety and Tolerability, Pharmacodynamic Effects and Exploratory Efficacy of a Vaccine Against Essential Hypertension
Phase 2
Completed
- Conditions
- Hypertension
- Interventions
- Biological: CYT006-AngQbBiological: Placebo
- First Posted Date
- 2008-06-19
- Last Posted Date
- 2009-12-02
- Lead Sponsor
- Cytos Biotechnology AG
- Target Recruit Count
- 60
- Registration Number
- NCT00701649
- Locations
- 🇨ðŸ‡
Inselspital, Bern, Switzerland
🇨ðŸ‡Hopital Universitaire Geneve, Geneva, Switzerland
🇨ðŸ‡University Hospital Basel, Basel, Switzerland
Effect of an Allergen Vaccine in Patients With Allergic Rhino-Conjunctivitis and Asthma Due to House Dust Mite Allergy
Phase 1
Completed
- Conditions
- Perennial Allergic RhinoconjunctivitisAllergic Asthma
- Interventions
- Biological: CYT005-AllQbG10
- First Posted Date
- 2008-04-03
- Last Posted Date
- 2008-04-09
- Lead Sponsor
- Cytos Biotechnology AG
- Target Recruit Count
- 21
- Registration Number
- NCT00652223
- Locations
- 🇨ðŸ‡
University Hospital Zurich, Department of Dermatology, Zurich, Switzerland
Safety and Immunogenicity of CYT004-MelQbG10 Vaccine With and Without Adjuvant in Advanced Stage Melanoma Patients
Phase 2
Completed
- Conditions
- Malignant Melanoma
- Interventions
- Biological: CYT004-MelQbG10 + MontanideBiological: CYT004-MelQbG10 + Montanide + ImiquimodBiological: CYT004-MelQbG10 + ImiquimodBiological: CYT004-MelQbG10 intra nodal injection
- First Posted Date
- 2008-04-03
- Last Posted Date
- 2010-11-15
- Lead Sponsor
- Cytos Biotechnology AG
- Target Recruit Count
- 21
- Registration Number
- NCT00651703
- Locations
- 🇨ðŸ‡
Dermatologische Klinik, UniversitätsSpital Zürich, Zurich, Switzerland
🇨ðŸ‡Ludwig Institute for Cancer Research; CHUV, Lausanne, VD, Switzerland
A Study to Investigate an Immunomodulatory Therapy in Adult Patients With Perennial Allergic Rhinoconjunctivitis
Phase 2
Completed
- Conditions
- Perennial Allergic RhinoconjunctivitisHouse Dust Mite Allergy
- Interventions
- Drug: CYT005-AllQbG10 (combination of house dust mite allergen extract with CYT003-QbG10)Drug: House dust mite allergen extract in combination with CYT003-QbG10-placebo
- First Posted Date
- 2007-12-17
- Last Posted Date
- 2009-04-27
- Lead Sponsor
- Cytos Biotechnology AG
- Target Recruit Count
- 100
- Registration Number
- NCT00574223
- Locations
- 🇨ðŸ‡
Cytos Biotechnology (Sponsor's Headquarter), Schlieren, Switzerland
© Copyright 2025. All Rights Reserved by MedPath